You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.
The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.
A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.
Athena and its supporters have asked the Supreme Court to clarify patent eligibility, but Mayo recently countered that this is a job for legislators.
Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.
10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.
According to the DOJ, the company also accepted a 25-year ban on participating in any federal healthcare program.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.
Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.
A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.
In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.